Sanofi India bets big on insulin and specialty care after restructuring
- Sanofi India managing director Deepak Arora says the company is focusing on insulin and specialty-care medicines after restructuring.
- Sanofi's insulin portfolio grew 14% in the September quarter, contributing around 60% of the company's revenue.
- • Deepak Arora said public-sector insulin sales jumped 85% as Sanofi expanded supplies to government hospitals and healthcare programmes.
- Sanofi plans new specialty-care launches, including Qfitlia, a haemophilia treatment expected to launch in India next year.
Source: moneycontrol.com
Get 100 stories a day on the app
Read, watch & listen · Free on iOS & Android



